Becton Dickinson and Company (BD) saw its share price fall by 3% after trimming its fiscal year 2026 (FY26) profit outlook. This adjustment follows the formal completion of the spin-off of its biosciences & diagnostic solutions business, which merged with Waters in a $17.5bn agreement. Despite the stock drop, BD reported stronger-than-expected Q1 FY2026 results, with profits of $5.25bn, a 1.6% rise from the previous year.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
BD shares fall by 3% after lowering FY26 profit outlook
Becton Dickinson and Company (BD) saw its share price fall by 3% after trimming its fiscal year 2026 (FY26) profit outlook. This adjustment follows the formal completion of the spin-off of its biosciences & diagnostic solutions business, which merged with Waters in a $17.5bn agreement. Despite the stock drop, BD reported stronger-than-expected Q1 FY2026 results, with profits of $5.25bn, a 1.6% rise from the previous year.